PainReform Ltd. (PRFX)

Market Cap	2.12M
Revenue (ttm)	n/a
Net Income (ttm)	-9.34M
Shares Out	2.47M
EPS (ttm)	-7.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,121
Open	0.835
Previous Close	0.890
Day's Range	0.825 - 0.870
52-Week Range	0.417 - 26.410
Beta	0.53
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2024

About PRFX

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 1, 2020
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: PRFX